ORGANIZATION

JPMA Renews Call for Social Security Not Reliant on Drug Price Cuts: FY2025 Policy

By Kohei Hori April 2, 2025

- Only subscribers can save articles.
  
  Sign In
  
  Subscribe

The Japan Pharmaceutical Manufacturers Association (JPMA) on April 1 announced a broad policy for its activities in FY2025, reiterating the need for the Japanese government to break away from its overdependence on drug price cuts in making its social security…

To read the full story

MOF Tells LDP Members Govt Can Address Inflation with Current Budget Policy
April 21, 2025
JPMA President Demands Rethink of Social Security Expenditure Cap
February 27, 2025
JPMA to Put Japan’s Social Security Spending Cap Up for Discussion: Exec
February 21, 2025

ORGANIZATION

BCG’s Takeda Questions Conditional Pricing for Regenerative Medicines
March 25, 2026
Industry Groups Push Mindset Shift to Streamline Japan’s Clinical Trials
March 24, 2026
FY2027 Off-Year Drug Price Revision Already Decided: Kenporen Director
March 24, 2026
FPMAJ Calls for Drug Price Hike, End to Off-Year Revisions in FY2026 Plan
March 23, 2026
JPMA Names Shionogi’s Go Takahashi as Managing Director
March 23, 2026

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

A “Core Industry” in Name Only? Drug Pricing Reform Leaves a Sour Taste

By Ken Yoshino

Japan’s FY2026 drug price revision, officially announced on March 5, has landed poorly with the pharmaceutical industry — and the…

COLUMN

The Strategic MSL: Beyond Data Delivery, It’s About Impact

By Philip Carrigan

I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…